Drug Trial Radar · NCT04623541
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
194
Actual
Start
Nov 25, 2020
Primary completion
Dec 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie; Eli Lilly and Company
- First posted
- Nov 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Richter's Syndrome (RS): * epcoritamab + lenalidomide * epcoritamab + R-CHOP (i.e., rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine \[Oncovin®\] and prednisone). The study includes participants with R/R or TN HR CLL (non-US participants only)/small lymphocytic lymphoma (SLL) and participants with RS. The trial consists of two parts, a dose-escalation phase (phase Ib) and an expansion phase (phase II). Participants with RS are only included in the expansion phase. Epcoritamab will be injected subcutaneously (under the skin). Standard-of-care and combination treatments (venetoclax, pirtobrutinib, lenalidomide, and R-CHOP) will be given either orally (by mouth) or intravenously (in a vein). Study details include: * Study duration will be up to 5 years after the last participant's first treatment in the trial. * The treatment duration for each participant will be between 12 months (1 year) and 24 months (2 years), depending upon the treatment arm assigned. * The visit frequency will be either weekly, every other week, or monthly, depending upon the part of the study. All participants will receive active drug; no one will be given placebo.
Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Richter's Syndrome
- Treatment-naïve High Risk Chronic Lymphocytic Leukemia
Interventions
EpcoritamabBiological
Epcoritamab will be administered subcutaneously in cycles of 28 days, (except Cycle 1 for high-dose cohorts = 35 days).
EpcoritamabBiological
Epcoritamab will be administered subcutaneously in cycles of 21 days and 28 days.
rituximab, cyclophosphamide, doxorubicin, vincristine and prednisoneDrug
R-CHOP will be administered intravenously (prednisone may be administered orally) in cycles of 21 days.
VenetoclaxDrug
Venetoclax tablets will be administered orally once daily during the 5-week ramp up period in cycles of 28 or 35 days each.
EpcoritamabBiological
Epcoritamab will be administered subcutaneously in cycles of 28 days.
LenalidomideDrug
Lenalidomide capsules will be administered once daily for 21 days in each cycle of 28 days.
EpcoritamabBiological
Epcoritamab will be administered subcutaneously in cycles of 28 days.
PirtobrutinibDrug
Pirtobrutinib tablets will be administered in cycles of 28 days.
EpcoritamabBiological
Epcoritamab will be administered subcutaneously in cycles of 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Phase and Safety Run-in (R/R CLL arm): Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: During the first cycle for low dose cohorts (Cycle length = 28 days) and for high dose cohorts (Cycle length = 35 days)
- Dose Escalation Phase and Safety Run-in: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to 5 years
- Dose Escalation Phase: Number of Participants with Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and Clinical Tumor Lysis Syndrome (CTLS)Time frame: Up to 5 years
- Expansion Phase: Overall Response Rate (ORR)Time frame: Up to 5 years
Locations
81 sites in 12 countries. Site status is shown where the registry gives one.
O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama
University of California Davis Medical Center Sacramento
California City, California
City of Hope National Medical Center
Duarte, California
Cedars-Sinai Medical Center
Los Angeles, California
David Geffen School of Medicine
Los Angeles, California
Stanford Cancer Center
Palo Alto, California
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Memorial Healthcare System
Pembroke Pines, Florida
National Institutes of Health
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Henry Ford Medical Group
Detroit, Michigan
Hackensack Meridian Hospital
Hackensack, New Jersey
Northwell Health Cancer Institute
Lake Success, New York
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
University of Pennsylvania School of medicine
Philadelphia, Pennsylvania
The University of Texas Southwestern Medical Centre
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
St. George Hospital
Kogarah, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Barwon Health
Geelong, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
AZ Sint-Jan
Bruges, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Fakultni nemocnice Brno
Brno, Czechia, Czechia
Fakultni nemocnice Olomouc
Olomouc, Czechia, Czechia
Vseobecna Fakultni Nemocnice
Prague, Nové Město, Czechia
Fakultni nemocnice Hradec Kralove
Hradec Králové, Nový Hradec Králové, Czechia
Fakultni Nemocnice Ostrava
Ostrava, Poruba, Czechia
Aalborg University Hospital
Aalborg, Denmark
Århus University Hospital
Aarhus, Denmark
Odense University Hospital
Odense, Denmark
Roskilde Sygehus
Roskilde, Denmark
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.